Table 1.
Demographic characteristics of study patients, stratified by time to adjuvant chemotherapy following esophagectomy.
| ≤45 Days (n=408)(%) | 46–60 Days (n=439)(%) | 61–75 Days (n=335)(%) | >75 Days (n=452)(%) | p-value | |
|---|---|---|---|---|---|
| Age (years, median) | 61 | 61 | 62 | 63 | 0.005 |
| Sex (female) | 53 (13) | 68 (16) | 52 (16) | 80 (18) | 0.30 |
| Race | 0.009 | ||||
| White | 386 (95) | 416 (96) | 310 (93) | 404 (90) | |
| Black | 13 (3) | 14 (3) | 14 (4) | 32 (7) | |
| Other | 6 (2) | 4 (1) | 8 (2) | 14 (3) | |
| Year of diagnosis, median (IQR) | 2007 (2005–2010) | 2007 (2005–2010) | 2007 (2005–2010) | 2008 (2006–2011) | <0.001 |
| Charlson-Deyo Comorbidity (CDCC) Score | 0.58 | ||||
| 0 | 306 (75) | 305 (70) | 245 (73) | 328 (73) | |
| 1 | 88 (22) | 109 (25) | 75 (22) | 100 (22) | |
| 2+ | 14 (3) | 25 (6) | 15 (5) | 24 (5) | |
| Insurance status | 0.02 | ||||
| Private | 225 (57) | 222 (51) | 161 (49) | 345 (80) | |
| Government | 164 (41) | 198 (46) | 167 (50) | 75 (17) | |
| None | 7 (2) | 13 (3) | 4 (1) | 11 (3) | |
| Facility location | 0.62 | ||||
| Metro | 323 (83) | 347 (82) | 259 (82) | 345 (80) | |
| Urban | 55 (14) | 71 (17) | 51 (16) | 75 (17) | |
| Rural | 11 (3) | 6 (1) | 5 (2) | 11 (3) | |
| Facility type | 0.006 | ||||
| Academic/research program | 138 (35) | 190 (45) | 153 (46) | 191 (42) | |
| Clinical stage | 0.48 | ||||
| 1 | 38 (19) | 47 (22) | 29 (20) | 55 (23) | |
| 2 | 61 (31) | 76 (36) | 57 (39) | 86 (35) | |
| 3 | 99 (50) | 91 (42) | 59 (41) | 191 (42) | |
| Pathologic stage | 0.12 | ||||
| 1 | 14 (4) | 8 (2) | 9 (3) | 8 (2) | |
| 2 | 141 (36) | 163 (39) | 140 (43) | 194 (44) | |
| 3 | 238 (61) | 247 (59) | 176 (54) | 236 (54) | |
| Margin status | 0.50 | ||||
| R0 | 310 (78) | 320 (75) | 268 (81) | 342 (79) | |
| R1 | 83 (21) | 104 (24) | 63 (19) | 90 (21) | |
| R2 | 2 (1) | 3 (1) | 1 (0) | 3 (0) | |
| Squamous histology | 40 (10) | 60 (14) | 42 (13) | 75 (17) | 0.03 |
| Number of adjuvant chemotherapy agents | 0.18 | ||||
| Single | 170 (31) | 175 (19) | 138 (37) | 194 (38) | |
| Multiple | 238 (69) | 264 (81) | 197 (63) | 258 (62) | |
| Perioperative radiation | 0.09 | ||||
| None | 116 (29) | 110 (25) | 93 (28) | 154 (34) | |
| Induction | 4 (1) | 3 (1) | 4 (1) | 2 (0.4) | |
| Adjuvant | 284 (70) | 324 (74) | 238 (71) | 293 (65) | |
| Sequence of adjuvant radiation and chemotherapy | 0.006 | ||||
| Concurrent | 86 (29) | 62 (19) | 43 (18) | 68 (22) | |
| Sequential | 202 (71) | 264 (81) | 195 (82) | 228 (78) | |
| Length of stay (median with IQR) | 9 (7–12) | 9 (7–12) | 10 (8–14) | 11 (8–18) | <0.001 |
| 30-day readmission | 27 (7) | 16 (4) | 20 (6) | 30 (7) | 0.18 |